Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported its financial results and business update for the full year and the three months ended December 31, 2016. …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated …
Advanced Micro Devices, Inc. (NASDAQ:AMD) shares are rising close to 5% in pre-market trading on back of yesterday evening’s release of fourth quarter …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced the pricing of its underwritten public offering of 20,325,204 shares of its common stock at a price to …
Yesterday morning, Ironwood (NASDAQ:IRWD) and Allergan (NYSE:AGN) announced that the FDA approved a lower dose (72mcg) of Linzess (linaclotide). The dosage levels approved for …
Oppenheimer analysts are chiming in with upbeat forecasts on two biotech players: Celgene Corporation (NASDAQ:CELG) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP). One analyst is out …
BTIG analyst Tim Chiang remains positive on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) following news of Allergan (NYSE:AGN) and Ironwood (NASDAQ:IRWD) receiving approval of their …
Allergan (NYSE:AGN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) announced this morning the approval of the 72 mcg formulation of Linzess for the treatment of chronic …
Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) constipation drug Trulance will compete directly with Ironwood Pharmaceuticals (NASDAQ:IRWD) and Allergan‘s (NYSE:AGN) drug Linzess, which received FDA approval this …
Canaccord analyst John Newman weighs in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), as competitor Ironwood Pharmaceuticals (NASDAQ:IRWD) has a PDUFA date of February 9, 2017 for …
